Clinical Trial Update: A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection [Phase 1, Phase 2]

View source ↗

Summary

This document updates a Phase 1/2 clinical study evaluating iNeo-Vac-R01, a neoantigen-based personalized mRNA therapy, in combination with a PD-1 inhibitor as …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PD-1 inhibitor
• iNeo-Vac-R01 (Neoantigen-based personalized mRNA therapy)

Snippet

Sponsor: Yinghua Xu | Conditions: Hepatocellular Carcinoma (HCC) | Phase 1, Phase 2 | Status: RECRUITING